Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)

The purpose of this FOA is to solicit applications for Liquid Biopsy Research Laboratories (LBRLs), one of the two components of the Precompetitive Collaboration on Liquid Biopsy for Early-Cancer Assessment Consortium (LBC). LBC is an Academic-Industrial Partnership program to develop and validate liquid biopsy technologies for early-cancer detection, risk assessment, and/or for distinguishing cancer from benign disease or aggressive from indolent cancers. The LBRLs will conduct research on the development of liquid biopsy technologies, assays and/or methods for the capture and analysis of tumor associated cells, DNA, RNA, or exosomes in body fluids of individuals with early-stage cancer or at high risk of developing the disease. Precompetitive alliances between academic and industry research teams must be integral to the LBRLs for more effective harmonization and successful validation of the developed liquid biopsy technologies, methods, and assays.

The other component of LBC is the Data Management and Coordination Unit (DMCU).